Sun Pharma has launched Kapspargo Sprinkle extended release capsules in the US, for the treatment of hypertension, angina pectoris and heart failure.
Kapspargo Sprinkle is an FDA approved, novel, patented formulation of metoprolol succinate.
It is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor blocking agent (beta-blocker).
Pellets can be sprinkled over soft food or administered via a nasogastric tube, and are designed to facilitate long-term, once-daily administration, particularly for patients who have difficulty swallowing.
“Roughly 40% of patients requiring long-term care have difficulty swallowing, a problem that may result in patient non-adherence to medications as well as medication errors,” said Abhay Gandhi, CEO-North America, Sun Pharma.
“Kapspargo Sprinkle capsules may make it easier for patients to take their antihypertensive medication. This innovative product is the latest example of Sun Pharma’s use of advanced technology to create novel formulations of proven medications.”